Sam Brusco, Associate Editor05.30.24
Kurin has announced that Christine Arme will be appointed as the company’s chief commercial officer.
Arme has been in the healthcare industry for 35 years, working in both startup and scaled health organizations. She was most recently VP of healthcare systems at Solventum (formerly 3M Health Care), where she was since 2015.
There she led the Key Account organization for the Medical Surgical business, the largest group within Solventum.
“I am pleased to announce Christine’s arrival to Kurin,” said Kurin CEO Bob Rogers. “She has had a storied career, including being one of the key reasons for our success at Ivera Medical, the creators of the market-leading Curos Port Protector, which was acquired by 3M in 2015.”
“Her continuing success and advancement in more senior roles since then have been a pleasure to watch and we are excited to have her return to our group,” Rogers went on. “Kurin has had a very successful stretch, mirroring the performance of Ivera Medical. We are in a great position to accelerate this growth and Christine’s skill, leadership, and energy are exactly what we need to take Kurin to the next level.”
“It’s like coming home to a familiar family that exudes a strong culture and a mission to improve healthcare, reduce costs and help clinicians and patients—all of which I am very passionate about,” Arme said.
The company’s U.S. Food and Drug Administration (FDA) 510(k)-cleared products have designs that require no further user steps. Kurin passively sidelines possible contaminants during blood culture collection.
Contaminated blood cultures cause about a third of positive results to be wrong. This exposes patients to unneeded antibiotics, extends hospital stays, and impacts antimicrobial resistance. The company’s Kurin Lock and Kurin Jet are tools clinicians can use to address these problems.
Arme has been in the healthcare industry for 35 years, working in both startup and scaled health organizations. She was most recently VP of healthcare systems at Solventum (formerly 3M Health Care), where she was since 2015.
There she led the Key Account organization for the Medical Surgical business, the largest group within Solventum.
“I am pleased to announce Christine’s arrival to Kurin,” said Kurin CEO Bob Rogers. “She has had a storied career, including being one of the key reasons for our success at Ivera Medical, the creators of the market-leading Curos Port Protector, which was acquired by 3M in 2015.”
“Her continuing success and advancement in more senior roles since then have been a pleasure to watch and we are excited to have her return to our group,” Rogers went on. “Kurin has had a very successful stretch, mirroring the performance of Ivera Medical. We are in a great position to accelerate this growth and Christine’s skill, leadership, and energy are exactly what we need to take Kurin to the next level.”
“It’s like coming home to a familiar family that exudes a strong culture and a mission to improve healthcare, reduce costs and help clinicians and patients—all of which I am very passionate about,” Arme said.
About Kurin
The certified Minority Business Enterprise (MBE) specializes in products that help reduce contaminated blood cultures.The company’s U.S. Food and Drug Administration (FDA) 510(k)-cleared products have designs that require no further user steps. Kurin passively sidelines possible contaminants during blood culture collection.
Contaminated blood cultures cause about a third of positive results to be wrong. This exposes patients to unneeded antibiotics, extends hospital stays, and impacts antimicrobial resistance. The company’s Kurin Lock and Kurin Jet are tools clinicians can use to address these problems.